Coronary artery bypass graft vs. percutaneous coronary angioplasty: CABG on the rebound?

Current Opinion in Cardiology

Volumn 22, Issue 6, 2007, Pages 517-523

  Taggart, David P ^a,b  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Coronary artery bypass grafting; Cost effectiveness; Diabetes; Drug eluting stents; Multidisciplinary team

Indexed keywords

ANTITHROMBOCYTIC AGENT;

BARE METAL STENT; CLINICAL FEATURE; COMPARATIVE STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DIABETIC PATIENT; DRUG ELUTING STENT; FINANCIAL MANAGEMENT; FREEDOM; HEALTH ECONOMICS; HEART INFARCTION; HUMAN; LEFT ANTERIOR DESCENDING CORONARY ARTERY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVIEW; RISK; STENT; SURVIVAL; THERAPY EFFECT; THROMBOSIS;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ARTERY BYPASS; CORONARY ARTERY DISEASE; COST-BENEFIT ANALYSIS; HUMANS;

EID: 35148876554     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/HCO.0b013e3282f001a2     Document Type: Review

References (59)

1. Dawkins KD, Gershlick T, de Belder M, et al. Joint Working Group on Percutaneous Coronary Intervention of the British Cardiovascular Intervention Society and the British Cardiac Society. Percutaneous coronary intervention: recommendations for good practice and training. Heart 2005; 91(Suppl 6):vi, 1-27.
2. Farb A, Boam MS. Stent thrombosis redux - the FDA perspective. N Engl J Med 2007; 356:984-987. Review of issues surrounding DES thrombosis.
3. Davies RF, Goldberg AD, Forman S, et al. Asymptomatic Cardiac Ischemia Pilot (ACIP) study two-year follow-up: outcomes of patients randomized to initial strategies of medical therapy versus revascularization. Circulation 1997; 95:2037-2043.
4. Yusuf S, Zucker D, Peduzzi P, et al. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration. Lancet 1994; 344:563-570.
5. Loop FD, Lytle BW, Cosgrove DM, et al. Influence of the internal-mammary-artery graft on 10-year survival and other cardiac events. N Engl J Med 1986; 314:1-6.
6. Aziz O, Rao C, Panesar SS, et al. Meta-analysis of minimally invasive internal thoracic artery bypass versus percutaneous revascularisation for isolated lesions of the left anterior descending artery. Br Med J 2007; 334:617-620. Meta-analysis of 12 studies (1952 patients) of minimally invasive left internal thoracic artery bypass for isolated lesions of the left anterior descending artery showed a higher rate of recurrent angina (odds ratio 2.6), incidence of major adverse coronary and cerebral events (OR 2.86), and need for repeat revascularisation (OR 4.6) with PCI but no significant difference in myocardial infarction, stroke, or mortality at median follow-up of 4 years.
7. Rao C, Aziz O, Panesar SS, et al. Cost effectiveness analysis of minimally invasive internal thoracic artery bypass versus percutaneous revascularisation for isolated lesions of the left anterior descending artery. Br Med J 2007; 334:621-623. Cost-effectiveness analysis showing that minimally invasive left internal thoracic artery bypass for isolated lesions of the left anterior descending artery may be a more cost-effective medium and long-term alternative to PCI.
8. Taggart DP, Thomas B. Ferguson Lecture. Coronary artery bypass grafting is still the best treatment for multivessel and left main disease, but patients need to know. Ann Thorac Surg 2006; 82:1966-1975. Extensive review of the PCI and CABG literature in multivessel and left main-stem CAD illustrating in particular how randomized trials were biased against the prognostic benefit of CABG.
9. BARI Investigators. The final 10-year follow-up results from the BARI randomized trial. J Am Coll Cardiol 2007; 49:1600-1606. Overall respective 10-year survival and reintervention rates in 1829 symptomatic patients with multivessel CAD was 71% and 77% for PCI and 74% and 20% for CABG. In the diabetic subgroup survival was better with CABG than PCI (58% vs. 46%).
10. Serruys PW, Ong AT, van Herwerden LA, et al. Five-year outcomes after coronary stenting versus bypass surgery for the treatment of multivessel disease: the final analysis of the Arterial Revascularization Therapies Study (ARTS) randomized trial. J Am Coll Cardiol 2005; 46:575-581.
11. Pepper JR. Five-year results from the Stent or Surgery (SoS) trial. Proceedings of the World Congress of Cardiology; 2-5 September 2006; Barcelona. At 5 years in 908 patients there was superior overall survival for CABG vs. PCI (93.4% vs. 89.1%) and particularly in 142 diabetic patients (94.6% vs. 82.4%).
12. Hoffman SN, TenBrook JA, Wolf MP, et al. A meta-analysis of randomized controlled trials comparing coronary artery bypass graft with percutaneous transluminal coronary angioplasty: one to eight-year outcomes. J Am Coll Cardiol 2003; 41:1293-1304.
13. Brener SJ, Lytle BW, Casserly IP, et al. Propensity analysis of long-term survival after surgical or percutaneous revascularization in patients with multivessel coronary artery disease and high-risk features. Circulation 2004; 109:2290-2295.
14. Hannan EL, Racz MJ, Walford G, et al. Long-term outcomes of coronary-artery bypass grafting versus stent implantation. N Engl J Med 2005; 352:2174-2183.
15. Malenka DJ, Leavitt BJ, Hearne MJ, et al., Northern New England Cardiovascular Disease Study Group. Comparing long-term survival of patients with multivessel coronary disease after CABG or PCI: analysis of BARI-like patients in northern New England. Circulation 2005; 112 (9 Suppl):I371-I376.
16. Smith PK, Califf RM, Tuttle RH, et al. Selection of surgical or percutaneous coronary intervention provides differential longevity benefit. Ann Thorac Surg 2006; 82:1420-1428.
17. Ragosta M, Dee S, Sarembock IJ, et al. Prevalence of unfavorable angiographic characteristics for percutaneous intervention in patients with unprotected left main coronary artery disease. Catheter Cardiovasc Interv 2006; 68:357-362. In 13 228 consecutive coronary angiograms, 476 (3.6%) patients had up to 60% stenosis of the left main. In 232 patients, six features were chosen as 'unfavourable' for PCI: (1) bifurcation disease, (2) occlusion of a major coronary, (3) ejection fraction under 30%, (4) occlusion of a dominant right coronary artery, (5) left dominant circulation, and (6) coexisting three-vessel disease. Unfavourable characteristics were common with at least one unfavourable characteristic seen in 80%. Bifurcation disease was the most common unfavourable characteristic observed (53%) and coexisting three-vessel disease was seen in 38%.
18. Jonsson A, Ivert T, Svane B, et al. Classification of left main coronary obstruction - feasibility of surgical angioplasty and survival after coronary artery bypass surgery. Cardiovasc Surg 2003; 11:497-505.
19. Keogh BE, Kinsman R. Fifth national adult cardiac surgical database report 2003. Henley-on Thames: Dendrite Clinical Systems; 2004.
20. Eagle KA, Guyton RA, Davidoff R, et al. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). Circulation 2004; 110:e340-e437.
21. Silber S, Albertsson P, Aviles FF, et al. Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Guidelines for percutaneous coronary interventions. Eur Heart J 2005; 26:804-847.
22. Smith SC Jr, Dove JT, Jacobs AK, et al. American Heart Association Task Force on Practice Guidelines. Committee to Revise the 1993 Guidelines for Percutaneous Transluminal Coronary Angioplasty. ACC/AHA guidelines of percutaneous coronary interventions (revision of the 1993 PTCA guidelines) - executive summary. J Am Coll Cardiol 2001; 37:2215-2239.
23. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al. American College of Cardiology/American Heart Association/Society for Cardiovascular Angiography and Interventions Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention. ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention - summary article. Circulation 2006; 113:156-175.
24. Kappetein AP, Dawkins KD, Mohr FW, et al. Current percutaneous coronary intervention and coronary artery bypass grafting practices for three-vessel and left main coronary artery disease. Insights from the SYNTAX run-in phase. Eur J Cardiothorac Surg 2006; 29:486-491. Current CABG and PCI practice was evaluated in 12 072 patients in 104 centres in 3 months in 2004. CABG was the most frequently performed procedure (74%) of which 71% were for three-vessel CAD and 29% for left main-stem stenosis. PCI was performed in 18% of the cases of left main-stemand/or three-vessel disease in the USA vs. 29% in Europe.
25. De Lezo JS, Medina A, Pan M, et al. Rapamycin-eluting stents for the treatment of unprotected left main coronary disease. Am Heart J 2004; 148:481-485.
26. Park SJ, Kim YH, Lee BK, et al. Sirolimus-eluting stent implantation for unprotected left main coronary artery stenosis: comparison with bare metal stent implantation. J Am Coll Cardiol 2005; 45:351-356.
27. Valgimigli M, van Mieghem CA, Ong AT, et al. Short- and long-term clinical outcome after drug-eluting stent implantation for the percutaneous treatment of left main coronary artery disease: insights from the Rapamycin-Eluting and Taxus Stent Evaluated At Rotterdam Cardiology Hospital registries (RESEARCH and T-SEARCH). Circulation 2005; 111:1383-1389.
28. Price MJ, Cristea E, Sawhney N, et al. Serial angiographic follow-up of sirolimus-eluting stents for unprotected left main coronary artery revascularization. J Am Coll Cardiol 2006; 47:871-877. Surveillance angiography was performed at 3 and 9 months' follow-up in 50 patients with unprotected left main-stem stenosis when restenosis increased from 34% to 44%. Restenosis is usually focal, most often involves the LCX ostium, and often occurs without symptoms.
29. Chieffo A, Morici N, Maisano F, et al. Percutaneous treatment with drug-eluting stent implantation versus bypass surgery for unprotected left main stenosis: a single-center experience. Circulation 2006; 113:2542-2547.
30. Kim YH, Park SW, Hong MK, et al. Comparison of simple and complex stenting techniques in the treatment of unprotected left main coronary artery bifurcation stenosis. Am J Cardiol 2006; 97:1597-1601. One hundred and sixteen patients with unprotected LMS stenosis underwent PCI with no incidents of death or myocardial infarction during median 18.6 months follow-up and 5% repeat revascularization.
31. Lee MS, Kapoor N, Jamal F, et al. Comparison of coronary artery bypass surgery with percutaneous coronary intervention with drug-eluting stents for unprotected left main coronary artery disease. J Am Coll Cardiol 2006; 47:864-870.
32. Palmerini T, Marzocchi A, Marrozzini C, et al. Comparison between coronary angioplasty and coronary bypass surgery for the treatment of unprotected left main coronary artery stenosis (the Bologna Registry). Am J Cardiol 2006; 98:54-59. One hundred and fifty-four patients with LMS CAD underwent CABG and 157 underwent PCI. At a median follow-up of 14 months, the respective rates of mortality were 12% and 13% and repeat revascularization rates were 3% and 26%.
33. Tanabe K, Hoye A, Lemos PA, et al. Restenosis rates following bifurcation stenting with sirolimus-eluting stents for de novo narrowings. Am J Cardiol 2004; 94:115-118.
34. Lemos PA, Hoye A, Goedhart D, et al. Clinical, angiographic, and procedural predictors of angiographic restenosis after sirolimus-eluting stent implantation in complex patients: an evaluation from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) study. Circulation 2004; 109:1366-1370.
35. Hoye A, Iakovou I, Ge L, et al. Long-term outcomes after stenting of bifurcation lesions with the 'crush' technique: predictors of an adverse outcome. J Am Coll Cardiol 2006; 47:1949-1958.
36. Valgimigli M, Malagutti P, Rodriguez-Granillo GA, et al. Distal left main coronary disease is a major predictor of outcome in patients undergoing percutaneous intervention in the drug-eluting stent era: an integrated clinical and angiographic analysis based on the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) and Taxus-Stent Evaluated At Rotterdam Cardiology Hospital (T-SEARCH) registries. J Am Coll Cardiol 2006; 47:1530-1537. 130 patients with (94 with distal) LMS stenosis received DES. After a median of 20 months the cumulative incidence of major adverse cardiac events was 30% in patients with distal disease vs. 11% in those without (P = 0.007) mainly driven by the different rate of target vessel revascularization (13% vs. 3%; P = 0.02).
37. Tan WA, Tamai H, Park SJ, et al. Long-term clinical outcomes after unprotected left main trunk percutaneous revascularization in 279 patients. Circulation 2001; 104:1609-1614.
38. Silvestri M, Barragan P, Sainsous J, et al. Unprotected left main coronary artery stenting: immediate and medium-term outcomes of 140 elective procedures. J Am Coll Cardiol 2000; 35:1543-1550.
39. Park SJ, Park SW, Hong MK, et al. Long-term (three-year) outcomes after stenting of unprotected left main coronary artery stenosis in patients with normal left ventricular function. Am J Cardiol 2003; 91:12-16.
40. Taggart DP, D'Amico R, Altman DG. Effect of arterial revascularisation on survival: a systematic review of studies comparing bilateral and single internal mammary arteries. Lancet 2001; 358:870-875.
41. Taggart DP, Lees B, Gray A, et al. ART Investigators. Protocol for the Arterial Revascularisation Trial (ART). A randomised trial to compare survival following bilateral versus single internal mammary grafting in coronary revascularisation [ISRCTN46552265]. Trials 2006; 7:7. A randomized trial to compare survival following bilateral vs. single internal mammary grafting in 3000 CABG patients.
42. Niles NW, McGrath PD, Malenka D, et al., Northern New England Cardiovascular Disease Study Group. Survival of patients with diabetes and multivessel coronary artery disease after surgical or percutaneous coronary revascularization: results of a large regional prospective study. J Am Coll Cardiol 2001; 37:1008-1015.
43. Hannan EL, Racz M, Holmes DR, et al. Impact of completeness of percutaneous coronary intervention revascularization on long-term outcomes in the stent era. Circulation 2006; 113:2406-2412. A total of 69% of all stent patients with multivessel CAD were incompletely revascularized, and 30% of all patients had total occlusions and/or at least two incompletely revascularized vessels. Incompletely revascularized patients were significantly more likely to die at any time (adjusted hazard ratio = 1.15) than completely revascularized patients. Those with total occlusions and at least two incompletely revascularized vessels were at the highest risk (HR = 1.36).
44. Katritsis DG, Ioannidis JP. Percutaneous coronary intervention versus conservative therapy in nonacute coronary artery disease: a meta-analysis. Circulation 2005; 111:2906-2912.
45. Boden WE, O'Rourke RA, Teo KK, et al., COURAGE Trial Research Group. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 2007; 356:1503-1516. Some 2287 patients who had objective evidence of myocardial ischemia and significant CAD were assigned to undergo PCI with optimal medical therapy (PCI group) or to optimal medical therapy alone (medical-therapy group). The 4.6-year cumulative primary-event rates were 19.0% in the PCI group and 18.5% in the medical-therapy group (P = 0.62). There were no significant differences between the PCI group and the medical-therapy group in the composite of death, myocardial infarction, stroke or hospitalization for acute coronary syndrome or myocardial infarction.
46. Babapulle MN, Joseph L, Belisle P, et al. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet 2004; 364:583-591.
47. Hill RA, Dundar Y, Bakhai A, et al. Drug-eluting stents: an early systematic review to inform policy. Eur Heart J 2004; 25:902-919.
48. Kaiser C, Brunner-La Rocca HP, et al., BASKET Investigators. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitats Trial (BASKET). Lancet 2005; 366:921-929.
49. Kastrati A, Mehilli J, Pache J, et al. Analysis of 14 trials comparing sirolimuseluting stents with bare-metal stents. N Engl J Med 2007; 35:1030-1039. An analysis of individual data on 4958 patients enrolled in 14 randomized trials comparing DES and BMS (mean follow-up interval, 12 to 59 months) showed no significant effect on overall long-term survival and survival free of myocardial infarction but a reduction in the need for reintervention with DES.
50. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. J Am Med Assoc 2005; 293:2126-2130.
51. Tung R, Kaul S, Diamond GA, Shah PK. Narrative review: drug-eluting stents for the management of restenosis: a critical appraisal of the evidence. Ann Intern Med 2006; 144:913-919. A critical reassessment of the published evidence questions the putative superiority of DES over BMS examining (a) overestimation of restenosis benefit, (b) underestimation of the risk for stent thrombosis, (c) overreliance on 'soft' rather than 'hard' outcomes (need for repeated revascularization vs. death or myocardial infarction), and (d) the attendant overestimation of cost-effectiveness.
52. Camenzind E, Gabriel Steg P, Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents. A cause for concern. Circulation 2007; 115:1440-1455.
53. Luscher TF, Steffel J, Eberli FR, et al. Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 2007; 115:1051-1058. The review focuses on the pathophysiological mechanisms and pathological findings of stent thrombosis in DES. Several factors are associated with an increased risk of stent thrombosis, including the procedure itself, patient and lesion characteristics, stent design and premature cessation of antiplatelet drugs, drugs released from DES impairing re-endothelialization resulting in a prothrombogenic environment, polymer-associated thrombosis and impairment of distal endothelial function.
54. Grines CL, Bonow RO, Casey DE Jr, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. J Am Coll Cardiol 2007; 49:734-739. This advisory stresses the importance of 12 months of dual antiplatelet therapy after placement of a DES and educating patients and healthcare providers about the hazards of premature discontinuation. It also recommends postponing elective surgery for 1 year, and, if surgery cannot be deferred, considering the continuation of aspirin during the perioperative period in high-risk patients with DES.
55. Griffin SC, Barber JA, Manca A, et al. Cost effectiveness of clinically appropriate decisions on alternative treatments for angina pectoris: prospective observational study. Br Med J 2007; 334:624-627. Prospective observational study comparing cost-effectiveness over 6-year follow-up of CABG, PCI or medical management within groups of patients rated as appropriate for revascularization. CABG seemed cost-effective but PCI did not and the clinical benefit of PCI may not be sufficient to justify its cost.
56. Hill R, Bagust A, Bakhai A, et al. Coronary artery stents: a rapid systematic review and economic evaluation. Health Technol Assess 2004; 8:1-242.
57. Taggart DP. Surgery is the best intervention for severe coronary artery disease. Br Med J 2005; 330:785-786.
58. Taggart DP. Coronary revascularisation. Br Med J 2007; 334:593-594.
59. Taggart DP. Coronary-artery stents. N Engl J Med 2006; 354:2076-2078.